Teyi Pharmaceutical Group Co Ltd Net Assets
Teyi Pharmaceutical Group Co Ltd net assets. Based on the latest financial reports, Teyi Pharmaceutical Group Co Ltd (002728) has net assets worth CN¥1.85 Billion CNY (≈ $270.32 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.33 Billion ≈ $340.67 Million USD) and total liabilities (CN¥480.81 Million ≈ $70.36 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Teyi Pharmaceutical Group Co Ltd (002728) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.85 Billion |
| % of Total Assets | 79.35% |
| Annual Growth Rate | 19.72% |
| 5-Year Change | 45.74% |
| 10-Year Change | 107.4% |
| Growth Volatility | 29.1 |
Net Assets of Teyi Pharmaceutical Group Co Ltd (2009–2025)
Net assets of Teyi Pharmaceutical Group Co Ltd from 2009 to 2025. This chart illustrates how Teyi Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. See Teyi Pharmaceutical Group Co Ltd (002728) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Teyi Pharmaceutical Group Co Ltd (2009–2025)
The table below shows the annual net assets of Teyi Pharmaceutical Group Co Ltd from 2009 to 2025. For live market cap and overall valuation, see Teyi Pharmaceutical Group Co Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.84 Billion ≈ $269.06 Million |
+4.18% |
| 2024-12-31 | CN¥1.76 Billion ≈ $258.27 Million |
-12.22% |
| 2023-12-31 | CN¥2.01 Billion ≈ $294.23 Million |
+43.30% |
| 2022-12-31 | CN¥1.40 Billion ≈ $205.32 Million |
+11.21% |
| 2021-12-31 | CN¥1.26 Billion ≈ $184.62 Million |
+16.78% |
| 2020-12-31 | CN¥1.08 Billion ≈ $158.10 Million |
-6.30% |
| 2019-12-31 | CN¥1.15 Billion ≈ $168.73 Million |
+3.76% |
| 2018-12-31 | CN¥1.11 Billion ≈ $162.60 Million |
+6.56% |
| 2017-12-31 | CN¥1.04 Billion ≈ $152.60 Million |
+17.63% |
| 2016-12-31 | CN¥886.57 Million ≈ $129.73 Million |
+10.23% |
| 2015-12-31 | CN¥804.30 Million ≈ $117.69 Million |
+9.33% |
| 2014-12-31 | CN¥735.64 Million ≈ $107.65 Million |
+110.10% |
| 2013-12-31 | CN¥350.14 Million ≈ $51.24 Million |
+22.71% |
| 2012-12-31 | CN¥285.34 Million ≈ $41.75 Million |
+26.53% |
| 2011-12-31 | CN¥225.51 Million ≈ $33.00 Million |
+32.02% |
| 2010-12-31 | CN¥170.81 Million ≈ $25.00 Million |
+65.55% |
| 2009-12-31 | CN¥103.18 Million ≈ $15.10 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Teyi Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2501.6% over the analyzed period, indicating profitable operations and earnings retention.
Teyi Pharmaceutical Group Co Ltd Net Assets Breakdown (December 2025)
Teyi Pharmaceutical Group Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥399.40 Million | 21.93% |
| Common Stock | CN¥513.31 Million | 28.18% |
| Other Comprehensive Income | CN¥159.98 Million | 8.78% |
| Other Components | CN¥748.78 Million | 41.11% |
| Total Equity | CN¥1.82 Billion | 100.00% |
Teyi Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Teyi Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Oneness Biotech Co Ltd
TWO:4743
|
$675.28 Million |
|
Manitowoc Company Inc
NYSE:MTW
|
$675.46 Million |
|
Udemy Inc
NASDAQ:UDMY
|
$675.68 Million |
|
Midland States Bancorp, Inc.
NASDAQ:MSBI
|
$675.69 Million |
|
Vats Liquor Chain Store Management Joint Stock Co Ltd
SHE:300755
|
$675.17 Million |
|
DAKOTA GOLD CORP. DL-001
F:RR6
|
$674.89 Million |
|
Dark Horse Beijing Technology Co Ltd
SHE:300688
|
$674.53 Million |
|
Naphtha
TA:NFTA
|
$674.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Teyi Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,764,933,238 to 1,821,466,000, a change of 56,532,762 (3.2%).
- Net income of 81,671,615 contributed positively to equity growth.
- Dividend payments of 24,946,612 reduced retained earnings.
- Share repurchases of 7,336,006 reduced equity.
- Other comprehensive income increased equity by 9,750,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥81.67 Million | +4.48% |
| Dividends Paid | CN¥24.95 Million | -1.37% |
| Share Repurchases | CN¥7.34 Million | -0.4% |
| Other Comprehensive Income | CN¥9.75 Million | +0.54% |
| Other Changes | CN¥-2.61 Million | -0.14% |
| Total Change | CN¥- | 3.20% |
Book Value vs Market Value Analysis
This analysis compares Teyi Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 16.80x to 2.47x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | CN¥0.54 | CN¥8.99 | x |
| 2010-12-31 | CN¥0.84 | CN¥8.99 | x |
| 2011-12-31 | CN¥1.07 | CN¥8.99 | x |
| 2012-12-31 | CN¥1.36 | CN¥8.99 | x |
| 2013-12-31 | CN¥1.19 | CN¥8.99 | x |
| 2014-12-31 | CN¥2.20 | CN¥8.99 | x |
| 2015-12-31 | CN¥2.07 | CN¥8.99 | x |
| 2016-12-31 | CN¥2.24 | CN¥8.99 | x |
| 2017-12-31 | CN¥2.65 | CN¥8.99 | x |
| 2018-12-31 | CN¥2.84 | CN¥8.99 | x |
| 2019-12-31 | CN¥2.88 | CN¥8.99 | x |
| 2020-12-31 | CN¥2.77 | CN¥8.99 | x |
| 2021-12-31 | CN¥3.14 | CN¥8.99 | x |
| 2022-12-31 | CN¥3.21 | CN¥8.99 | x |
| 2023-12-31 | CN¥4.37 | CN¥8.99 | x |
| 2024-12-31 | CN¥3.44 | CN¥8.99 | x |
| 2025-12-31 | CN¥3.65 | CN¥8.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Teyi Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.92%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.27x
- Recent ROE (4.48%) is below the historical average (14.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 23.36% | 11.92% | 1.07x | 1.84x | CN¥13.78 Million |
| 2010 | 28.09% | 19.13% | 0.99x | 1.48x | CN¥30.90 Million |
| 2011 | 30.91% | 22.84% | 1.08x | 1.26x | CN¥47.14 Million |
| 2012 | 27.54% | 23.06% | 0.88x | 1.36x | CN¥50.04 Million |
| 2013 | 23.01% | 23.50% | 0.76x | 1.30x | CN¥45.54 Million |
| 2014 | 10.90% | 23.26% | 0.42x | 1.12x | CN¥6.63 Million |
| 2015 | 10.08% | 15.70% | 0.32x | 1.99x | CN¥675.46K |
| 2016 | 10.69% | 14.45% | 0.41x | 1.81x | CN¥6.12 Million |
| 2017 | 10.20% | 15.48% | 0.36x | 1.85x | CN¥2.06 Million |
| 2018 | 14.00% | 17.58% | 0.43x | 1.86x | CN¥44.43 Million |
| 2019 | 14.89% | 18.64% | 0.41x | 1.96x | CN¥56.41 Million |
| 2020 | 4.06% | 6.93% | 0.28x | 2.09x | CN¥-64.23 Million |
| 2021 | 10.06% | 16.74% | 0.37x | 1.64x | CN¥748.41K |
| 2022 | 12.70% | 20.10% | 0.35x | 1.81x | CN¥37.89 Million |
| 2023 | 12.59% | 23.72% | 0.42x | 1.25x | CN¥52.11 Million |
| 2024 | 1.16% | 2.98% | 0.29x | 1.36x | CN¥-156.00 Million |
| 2025 | 4.48% | 8.92% | 0.40x | 1.27x | CN¥-100.47 Million |
Industry Comparison
This section compares Teyi Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,405,673
- Average return on equity (ROE) among peers: 7.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Teyi Pharmaceutical Group Co Ltd (002728) | CN¥1.85 Billion | 23.36% | 0.26x | $675.27 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $488.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $560.87 Million | 4.60% | 0.22x | $360.39 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.02 Billion | 12.46% | 0.13x | $4.73 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.04 Billion | 4.29% | 0.46x | $2.58 Billion |
| Wedge Industrial Co Ltd (000534) | $0.00 | 0.00% | 0.00x | $1.20 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $18.14 Billion | 17.33% | 0.53x | $14.52 Billion |
| Hainan Haiyao Co Ltd (000566) | $491.82 Million | 6.71% | 1.19x | $755.58 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $280.91 Million | 1.46% | 1.58x | $272.98 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.57 Billion | 7.36% | 1.59x | $920.83 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $7.25 Billion | 17.08% | 0.09x | $3.02 Billion |
About Teyi Pharmaceutical Group Co Ltd
Teyi Pharmaceutical Group Co.,Ltd engages in the research and development, production, and sale of Chinese patented medicines, pharmaceutical preparations, raw materials, and products in the People's Republic of China. The company's products are used in respiratory system, cardiovascular and cerebrovascular, respiratory, cardiovascular, and digestive systems. The company was formerly known as Gua… Read more